Last reviewed · How we verify

NCT03406689

Comparison of the Efficacy of Nepafenac 0.1% and Nepafenac 0.3 % on Pain Associated With Intravitreal Injections

Completed NA Last updated 4 April 2018
What this trial tests

NA trial testing Nepafenac 0.1% Oph Susp in Pain in 99 participants. Completed in 28 March 2018.

Timeline
1 September 2017
Primary endpoint
28 February 2018
28 March 2018

Quick facts

Lead sponsorUniversity Hospital of Patras
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposesupportive care
Enrollment99
Start date1 September 2017
Primary completion28 February 2018
Estimated completion28 March 2018
Sites1 location across Greece

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital of Patras

Who can join

18 and older, any sex, with Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The analgestic efffect of Nepafenac 0.1% Eye Drops and Nepafenac 0.3% Eye Drops on pain related to intravitreal injections will be evalutated. Pain perception will be assessed by the Short Form of the McGill Pain Questionnaire.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Nepafenac 0.1% Oph Susp

Trials testing the same drug.

Other recruiting trials for Pain

Currently open trials in the same condition.

Other University Hospital of Patras trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03406689.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing